Oral tolerance to low dose β₂-glycoprotein I: Immunomodulation of experimental antiphospholipid syndrome

Keyphrases

• Immunomodulation 100%
• Antiphospholipid Syndrome 100%
• β2-glycoprotein I (β2GPI) 100%
• Oral Tolerance 100%
• T Cells 16%
• Low Incidence 5%
• Specific Response 5%
• Disease Stage 5%
• Clinical Manifestations 5%
• Autoantigen 5%
• Thrombocytopenia 5%
• Balb C Mice 5%
• Immunization 5%
• Serum Biomarkers 5%
• Clinical Markers 5%
• Immunomodulatory Effect 5%
• Value of Time 5%
• CD8+ T Cells 5%
• Oral Administration 5%
• Low Titer 5%
• MHC Class I 5%
• Proliferation Inhibition 5%
• CD8+ Cells 5%
• Fetal Resorption 5%
• Disease Expression 5%
• Anticardiolipin 5%
• T Lymphocyte Proliferation 5%
• Activated Partial Thromboplastin Time (aPTT) 5%
• Cytolytic Activity 5%
• Lymphocyte Proliferation Response 5%

Immunology and Microbiology

• Glycoprotein 100%
• Low Drug Dose 100%
• Immunomodulation 100%
• Antiphospholipid Syndrome 100%
• T Cell 22%
• Titer 5%
• Autoantigen 5%
• Bagg Albino Mouse 5%
• Lymphocyte Proliferation 5%
• Cytotoxic T-Cell 5%
• CD8+ Cell 5%
• MHC Class I 5%
• Thromboplastin 5%

Pharmacology, Toxicology and Pharmaceutical Science

• Glycoprotein 100%
• Immunomodulation 100%
• Antiphospholipid Syndrome 100%
• Diseases 16%
• CD8 Antigen 11%
• Bagg Albino Mouse 5%
• Thrombocytopenia 5%
• Thromboplastin 5%
• Autoantigen 5%
• Fetus Resorption 5%